The TELIGAN 104-week data provide strong evidence of kidney function preservation and disease progression reduction, which could support global regulatory filings for telitacicept in IgAN. Monitor Vor Bio's interactions with FDA/EMA regarding acceptance of China-generated data and progress of its global Phase 3 programs in myasthenia gravis and Sjögren's disease.
Price Chart
Executive Summary
Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, showing a statistically significant annualized eGFR slope of -0.6 vs -5.7 mL/min/1.73 m²/year for placebo (p<0.001), an 89% reduction in risk of ≥30% eGFR decline, and durable proteinuria reduction. These data strengthen the case for dual BAFF/APRIL inhibition in IgAN and support Vor Bio's global Phase 3 programs in myasthenia gravis and Sjögren's disease, though the trial was conducted solely in China by collaborator RemeGen and may not be predictive of results in other populations.
Key Facts
- Annualized eGFR slope through 104 weeks: -0.6 mL/min/1.73 m²/year for telitacicept vs -5.7 for placebo (p<0.001)
- 89% reduction in risk of confirmed ≥30% eGFR decline (HR 0.11) and 81% reduction for ≥40% eGFR decline (HR 0.19)
- No telitacicept patient experienced a composite kidney failure endpoint vs five in placebo group
- 24h-UPCR decreased 60.3% from baseline at Week 104 vs 0.9% increase for placebo (placebo-adjusted reduction 60.7%)
- 44.0% of telitacicept patients achieved 24h-UPCR <0.5 g/g vs 8.2% for placebo
- Serious adverse events: 8.2% telitacicept vs 18.2% placebo
- Telitacicept received conditional approval in China for IgAN in June 2026; Vor Bio holds ex-Greater China rights
Financial Impact
Vor Bio is a clinical-stage company with no approved products in its territories; the positive Phase 3 data supports potential regulatory filings in US, EU, and Japan for IgAN and ongoing Phase 3 trials in myasthenia gravis and Sjögren's disease, but no revenue or deal value was disclosed
Risk Factors
- TELIGAN was conducted solely in China by RemeGen; FDA and other regulators may not accept data generated in China
- Conditional approval in China may be withdrawn or not converted to full approval
- Vor Bio relies on RemeGen for clinical data and drug supply
- Competition from other BAFF and/or APRIL inhibitors
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386893 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $18.26 $18.33 | ▲ +0.38% | ▼ −0.33% | $18.33 (+0.38%) |
Oct 5, 2026 21d ago | Press Release | $18.31 $18.78 | ▲ +2.57% | ▲ +2.81% | $18.33 (+0.11%) |
Sep 29, 2026 27d ago | Press Release | $18.33 $19.08 | ▲ +4.09% | ▲ +4.30% | $18.33 (−0.00%) |
Aug 11, 2026 10w ago | Press Release | $23.37 $22.34 | ▼ −4.41% | ▼ −4.66% | $18.33 (−21.57%) |
Jul 9, 2026 15w ago | 3 | $19.14 $18.03 | ▼ −5.80% | ▼ −5.03% | $18.33 (−4.23%) |
Jun 11, 2026 19w ago | Institutional Cluster | $14.09 $14.36 | ▲ +1.92% | ▲ +1.38% | $18.33 (+30.09%) |
Jun 8, 2026 20w ago | Press Release | $13.29 $13.28 | ▼ −0.08% | ▲ +0.22% | $18.33 (+37.92%) |
May 7, 2026 24w ago | EFFECT | $16.08 $16.94 | ▲ +5.35% | ▲ +4.52% | $18.33 (+13.99%) |
Apr 27, 2026 26w ago | S-3 | $14.38 $14.11 | ▼ −1.88% | ▼ −1.87% | $18.33 (+27.47%) |
Apr 27, 2026 26w ago | DEFA14A | $14.38 $14.11 | ▼ −1.88% | ▼ −1.87% | $18.33 (+27.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers